AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23639189 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroethanolic extract of Lippia alba leaves
Number of subjects: 21
Study 23639498 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent obtained on the day of surgery
Number of subjects: 2
Study 23639498 — intervention group
Group type: COMPARATOR
Intervention: Consent obtained before the day of surgery
Number of subjects: 2
Study 23640206 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 28
Study 23640206 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 28
Study 23640671 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 385
Study 23640671 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 385
Study 23641946 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm function assessed by twitch tracheal pressure in response to bilateral anterior magnetic phrenic nerve stimulation (Ptr,stim) on Day 1
Number of subjects: 85
Study 23641946 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in ICU survivors
Number of subjects: 85
Study 23641946 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in ICU nonsurvivors
Number of subjects: 85
Study 23641946 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in hospital survivors
Number of subjects: 85
Study 23641946 — intervention group
Group type: COMPARATOR
Intervention: Diaphragm function on Day 1 in hospital nonsurvivors
Number of subjects: 85
Study 23641946 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of low Ptr,stim
Number of subjects: 85
Study 23642342 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term implanted seizure advisory system
Number of subjects: 15
Study 23642526 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC (5-fluorouracil 600 mg/m(2), epirubicin 90 mg/m(2), cyclophosphamide 600 mg/m(2)) followed by weekly paclitaxel (80 mg/m(2)) with bevacizumab 10 mg/kg every 2 weeks
Number of subjects: 56
Study 23642625 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with paclitaxel 135 mg/m(2) and carboplatin AUC 5 every 3 weeks for 3 cycles
Number of subjects: 71
Study 23642625 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with paclitaxel/carboplatin
Number of subjects: 71
Study 23642924 — intervention group
Group type: EXPERIMENTAL
Intervention: Protégé EverFlex Self-Expanding Peripheral Stent System
Number of subjects: 287
Study 23643429 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23643486 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafe beclometasone (first ICS)
Number of subjects: 30354
Study 23643486 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrafe beclometasone (switched from another ICS)
Number of subjects: 30354
Study 23643560 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-modified endovascular graft (PMEG)
Number of subjects: 26
Study 23643591 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking
Number of subjects: 0
Study 23643591 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking
Number of subjects: 0
Study 23643595 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin levels <14 pmol/L combined with cardiac troponin I (cTnI) <99th percentile
Number of subjects: 1967
Study 23643595 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin >14 pmol/L
Number of subjects: 1967
Study 23643595 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of copeptin and cTnI
Number of subjects: 1967
Study 23643595 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal copeptin and cTnI
Number of subjects: 1967
Study 23644082 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter valve therapy (TVT) devices
Number of subjects: 0
Study 23644181 — intervention group
Group type: EXPERIMENTAL
Intervention: Average absolute Ecc-mid lower than -16.9%
Number of subjects: 1768
Study 23644181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecc-mid
Number of subjects: 1768
Study 23644181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecc-mid added to risk factors, LV ejection fraction, and LV mass index
Number of subjects: 1768
Study 23644181 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential strain
Number of subjects: 1768
Study 23644386 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y radioembolization
Number of subjects: 56
Study 23644386 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 56
Study 23645402 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiles of exhaled volatile organic compounds (VOCs)
Number of subjects: 40
Study 23645402 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values of patients with exacerbation
Number of subjects: 40
Study 23645402 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled nitric oxide fraction (FeNO) and lung function
Number of subjects: 40
Study 23645591 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued treatment with MAPK inhibitors (BRAF and MEK inhibitors) after disease progression
Number of subjects: 0
Study 23645591 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPK inhibitors (dabrafenib, trametinib, or combination)
Number of subjects: 0
Study 23645591 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term melanoma cultures from resistant tumor biopsies treated with MAPK inhibitors
Number of subjects: 0
Study 23645694 — intervention group
Group type: EXPERIMENTAL
Intervention: escalated dose subcutaneous alemtuzumab (starting at 30 mg three times per week, escalating to 90 mg weekly) with rituximab (375 mg/m² weekly)
Number of subjects: 28
Study 23645694 — intervention group
Group type: EXPERIMENTAL
Intervention: escalated dose subcutaneous alemtuzumab with rituximab
Number of subjects: 28
Study 23645911 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation of a question prompt sheet to increase patient involvement during consultation.
Number of subjects: 0
Study 23645911 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 23646035 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone mood ratings
Number of subjects: 40
Study 23646035 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil mood ratings
Number of subjects: 40
Study 23646111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy
Number of subjects: 587
Study 23646111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Caucasian ethnicity)
Number of subjects: 587
Study 23646111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Black ethnicity)
Number of subjects: 587
Study 23646111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Caucasian ethnicity, demographically adjusted)
Number of subjects: 587
Study 23646111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable combination antiretroviral therapy (Black ethnicity, demographically adjusted)
Number of subjects: 587
Study 23647568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP 180-load
Number of subjects: 117
Study 23647568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP variability
Number of subjects: 117
Study 23647568 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum BP increases from baseline and SBP and MAP loads
Number of subjects: 117
Study 23647688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release acetaminophen
Number of subjects: 188
Study 23647688 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 188
Study 23647688 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 188
Study 23647688 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication factors (side effects, out-of-pocket costs, mode of action, treatment schedule)
Number of subjects: 188
Study 23647688 — intervention group
Group type: COMPARATOR
Intervention: Patient characteristics
Number of subjects: 188
Study 23647704 — intervention group
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Number of subjects: 150
Study 23647796 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA occlusion
Number of subjects: 457
Study 23647796 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral vessels (0 to 3 collaterals)
Number of subjects: 457
Study 23647796 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral vessels (4 to 7 collaterals)
Number of subjects: 457
Study 23647796 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral vessels (≥8 collaterals)
Number of subjects: 457
Study 23648011 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 2017
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cortisol
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated cortisol
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal cortisol
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta cortisol
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol/DHEA ratio
Number of subjects: 231
Study 23650556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol/DHEAS ratio
Number of subjects: 231
Study 23651760 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital delirium
Number of subjects: 53
Study 23651760 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital delirium (but free of delirium at follow-up)
Number of subjects: 53
Study 23651760 — intervention group
Group type: COMPARATOR
Intervention: Few or no signs of depression at follow-up
Number of subjects: 53
Study 23651760 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattention
Number of subjects: 53
Study 23652269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalfampridine (0.5-2.0 mg/kg)
Number of subjects: 0
Study 23652269 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 23652845 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced angiographic sequences
Number of subjects: 274
Study 23652845 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced angiographic sequences
Number of subjects: 274
Study 23652845 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion sequences
Number of subjects: 274
Study 23656846 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime Axis I unipolar mood or anxiety diagnosis
Number of subjects: 121
Study 23656846 — intervention group
Group type: COMPARATOR
Intervention: No lifetime Axis I unipolar mood or anxiety diagnosis
Number of subjects: 121
Study 23657072 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent vaginal cleansing (baseline reported)
Number of subjects: 440
Study 23657072 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use (CCU) with primary partner
Number of subjects: 440
Study 23657072 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal candidiasis (treated as time-dependent variable)
Number of subjects: 440
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Borrelia burgdorferi
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Varicella zoster virus
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Herpes simplex virus 1
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Otitis media
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Human herpesvirus 6
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoplasma pneumoniae
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofibromatosis
Number of subjects: 46
Study 23657208 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal age facial palsy
Number of subjects: 46
Study 23657417 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC) with 1% metronidazole, ciprofloxacin, and cefaclor (GA)
Number of subjects: 45
Study 23657417 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer cement (GC) (Vidrion F)
Number of subjects: 45
Study 23657550 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial LAA clip device
Number of subjects: 40
Study 23658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 156
Study 23659317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m2) and cisplatin (75 mg/m2) combination therapy
Number of subjects: 73
Study 23659903 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis Physical Activity & Exercise Net (OPEN)
Number of subjects: 252
Study 23659903 — intervention group
Group type: COMPARATOR
Intervention: OA education pamphlet
Number of subjects: 252
Study 23659903 — intervention group
Group type: EXPERIMENTAL
Intervention: OPEN
Number of subjects: 252
Study 23659903 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness test
Number of subjects: 252
Study 23660412 — intervention group
Group type: EXPERIMENTAL
Intervention: Subway
Number of subjects: 97
Study 23660412 — intervention group
Group type: COMPARATOR
Intervention: McDonald's
Number of subjects: 97
Study 23660579 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-derived bovine immunoglobulin (SBI) 2.5 g twice daily for 8 weeks
Number of subjects: 8
Study 23660685 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting aberrant epigenetics
Number of subjects: 0
Study 23661292 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC1 protein expression
Number of subjects: 691
Study 23661292 — intervention group
Group type: EXPERIMENTAL
Intervention: MUC1 mRNA expression
Number of subjects: 691
Study 23661575 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme (30 min duration, four times a week)
Number of subjects: 280
Study 23661575 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity programme
Number of subjects: 280
Study 23661575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study 23662829 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK Nasal-12 (12-item nasal morbidity instrument)
Number of subjects: 104
Study 23663091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (3-month prospective period)
Number of subjects: 183
Study 23663490 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment for bipolar disorder
Number of subjects: 2896
Study 23663490 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rate of mood episodes
Number of subjects: 2896
Study 23663490 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication use during episodes
Number of subjects: 2896
Study 23663490 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatments
Number of subjects: 2896
Study 23663490 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare resource use
Number of subjects: 2896
Study 23663535 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR tagging with harmonic phase (HARP) method
Number of subjects: 25
Study 23663868 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based functional walking program
Number of subjects: 9
Study 23663870 — intervention group
Group type: EXPERIMENTAL
Intervention: WELCH questionnaire
Number of subjects: 434
Study 23663870 — intervention group
Group type: COMPARATOR
Intervention: WIQ questionnaire
Number of subjects: 434
Study 23663870 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic curve for WELCH
Number of subjects: 434
Study 23664013 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) given concurrently with chemotherapy for a total of eight doses over 36 weeks.
Number of subjects: 24
Study 23664013 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) at a maximum tolerated dose (MTD) of 2.3 mg/m(2) (max 4 mg) combined with conventional chemotherapy.
Number of subjects: 24
Study 23664414 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 8 weeks
Number of subjects: 24
Study 23664414 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 24
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: COMPARATOR
Intervention: Inframammary incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Subpectoral placement
Number of subjects: 0
Study 23664574 — intervention group
Group type: COMPARATOR
Intervention: Subglandular placement
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured surface/round/silicone-filled devices
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured surface/shaped/highly cohesive silicone-filled devices
Number of subjects: 0
Study 23664574 — intervention group
Group type: COMPARATOR
Intervention: Smooth surface/round/silicone-filled devices
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured surface devices
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe malposition with periareolar incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-severe malposition with axillary incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: COMPARATOR
Intervention: Moderate-severe malposition with inframammary incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary procedures with periareolar incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary procedures with axillary incision
Number of subjects: 0
Study 23664574 — intervention group
Group type: COMPARATOR
Intervention: Secondary procedures with inframammary incision
Number of subjects: 0
Study 23664596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/d for 7 days
Number of subjects: 30
Study 23664596 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 4 g/day for 28 days
Number of subjects: 30
Study 23664596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and fish oil for 7 days
Number of subjects: 30
Study 23664596 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 30
Study 23664596 — intervention group
Group type: COMPARATOR
Intervention: Fish oil alone
Number of subjects: 30
Study 23664596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aspirin and fish oil
Number of subjects: 30
Study 23665071 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 70
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on Schedule 2/2 plus S-1 (80-120 mg/day)/cisplatin 60 mg/m²
Number of subjects: 27
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on continuous daily dosing (CDD)
Number of subjects: 27
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg/day on Schedule 2/2
Number of subjects: 27
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day on Schedule 2/2
Number of subjects: 27
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall MTD cohort (n=16)
Number of subjects: 27
Study 23665950 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen (sunitinib plus S-1/cisplatin)
Number of subjects: 27
Study 23666316 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg QW + MTX for 36 weeks
Number of subjects: 834
Study 23666316 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) + MTX
Number of subjects: 834
Study 23666573 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline dosing regimen (exact dosage not specified)
Number of subjects: 100
Study 23666573 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1A2 genotypes (CYP1A2*1C and CYP1A2*1F)
Number of subjects: 100
Study 23666573 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation using data from an additional 27 patients
Number of subjects: 100
Study 23667161 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility assessment survey
Number of subjects: 64
Study 23667266 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dose quadrivalent HPV vaccine series (HPV-6, -11, -16, -18)
Number of subjects: 99
Study 23667315 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID
Number of subjects: 2497
Study 23667315 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 2497
Study 23667487 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500 mg daily
Number of subjects: 16
Study 23668549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg)
Number of subjects: 20
Study 23668924 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (mean dose 2.4±1.4 mg/24 h)
Number of subjects: 684
Study 23668924 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (starting doses: 1 mg/24 h for 85% of de novo patients, 1 mg/24 h for 50% of pretreated patients, 2 mg/24 h for 40% of pretreated patients)
Number of subjects: 684
Study 23669289 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir) for 48 weeks
Number of subjects: 497
Study 23669289 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (pegylated interferon/ribavirin with boceprevir or telaprevir)
Number of subjects: 497
Study 23670699 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 168